Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days).
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection
Basic Information
Important information about this medicine
About This Medicine
General information about this product
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days).
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days).
This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021. Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries.
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup. This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis). Patients should be monitored during and at least 1 hour after the injection.
The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, let your doctor know immediately.
Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions. Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug. This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.
Contact Us
If you want to know about the medicine availability or need help to identify where you can get it administered, please fill in your details here and we will reach out to you.
03Uses
Treatment of Mild to moderate Coronavirus disease (COVID-19)
04How To Use
Your doctor or nurse will give you this medicine. Kindly do not self administer.
05How It Works
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is a combination of two human immunoglobulins G-1 (IgG1), neutralizing monoclonal antibodies, that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is equally effective against the existing as well as newer emerging variants and prevents the virus from attaching to the human cell receptors.
06What If You Miss A Dose?
Q: What if you forget to take Casirivimab & Imdevimab Injection?
A: If you miss a dose of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, please consult your doctor.
07Benefits
In Treatment of Mild to moderate Coronavirus disease (COVID-19)
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains monoclonal antibodies that help manage mild to moderate COVID-19 symptoms in those individuals who are at a high risk of developing severe COVID-19 infection and do not need oxygen administration. This medicine may help you to recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with an infected person, or feel any of the symptoms, consult your doctor immediately.
08Side Effects
Injection site reactions (pain, swelling, redness)
Fever
Flushing (sense of warmth in the face, ears, neck and trunk)
Breathlessness
Chest tightness
Nausea
Vomiting
09Safety Information
Alcohol:CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection. Please consult your doctor.
Pregnancy:CONSULT YOUR DOCTOR
Information regarding the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection during pregnancy is not available. Please consult your doctor.
Breast feeding:CONSULT YOUR DOCTOR
Information regarding the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection during breastfeeding is not available. Please consult your doctor.
Driving:SAFE
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection does not usually affect your ability to drive.
Kidney:SAFE IF PRESCRIBED
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection may not be needed in these patients. Please consult your doctor.
Liver:CONSULT YOUR DOCTOR
There is limited information available on the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection in patients with liver disease. Please consult your doctor.
10Drug Tips
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, a monoclonal antibody cocktail therapy, is used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents aged 12 years and older, who weigh at least 40 kg.
The use of monoclonal antibodies is not indicated in severe hospitalized cases of COVID-19 or in those who require oxygen therapy.
Even after the treatment, you should continue to practice (COVID)-appropriate behavior such as wearing a mask, social distancing, avoiding sharing personal items, and frequent handwashing.
Before taking this antibody cocktail therapy, inform your doctor if you have any underlying medical conditions like diabetes, heart disease, high blood pressure, kidney disease, asthma, etc.
Patients should be monitored during treatment and at least one hour after the completion of the infusion.
Severe allergic reactions might happen during and after the use of monoclonal antibodies. Inform your doctor or nurse immediately if you experience shortness of breath, rapid or slow heart rate, chest pain, swelling of the face or lips, sweating.
References
Sources and references
Clinica Trials Arena. REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19. [Accessed 07 Jul. 2021] (online) Available from: View
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51. [Accessed 07 Jul. 2021] (online) Available from: View
Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015. [Accessed 6th Jan. 2022] (online) Available from: View
Cipla. Mumbai, 24th May 2021. Press Release: Roche & Cipla announce the arrival of the first batch of the new antibody cocktail drug (Casivirimab and Imdevimab) in India. [Accessed 06 Jan. 2022] (online) Available from: View
